JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.